海外の治験の状況「前立腺癌」での検索結果
161件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Recruiting
- EFFICACY AND SAFETY OF AB1010 IN COMBINATION WITH DOCETAXEL TO PLACEBO IN COMBINATION WITH DOCETEXAL IN FIRST LINE METASTATIC CASTRATE RESISTANT PROSTATE CANCER (mCRPC)
- first line metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Austria, Canada, Czech Republic, France, Germany, India, Poland, Slovakia, Taiwan, United States of America
- 2015-10-14
Not Recruiting
- A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Austria, Belgium, Germany, India, Netherlands, Poland, Russian Federation, South Africa, United Kingdom, United States
- 2012-04-30
Not Recruiting
- An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Austria, Czech Republic, Germany, Lithuania, Poland, Slovakia, Taiwan, Province of China, United States
- 2015-10-29
Not Recruiting
- A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
- Metastatic Castration- Resistant Prostate Cancer (mCRPC);C61 - Malignant neoplasm of prostate
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Finland, France, Germany, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Spain, Sweden, Taiwan, Province of China, United Kingdom, United States
- 2014-10-01
Recruiting
- PRospective Prostate biOmarker Study
- Indication for Prostate Biopsy Due to Suspected Prostate Cancer
- Austria, Denmark, Germany
- 2018-06-07
Not Recruiting
- PET/CT (positron emission tomography/computed tomography) imaging using [68Ga]RM2 (radioactive PET tracer) for detection of tumors in patients with primary prostate cancer.
- Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned. MedDRA version: 18.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01];Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned. MedDRA version: 18.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01];Patients with primary prostate cancer in which prostate cancer is histologically confirmed and a prostatectomy is planned. MedDRA version: 18.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
- Austria, Finland, United States
- 2015-02-18
Authorised
- A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
- Metastatic Castrate-Resistant Prostate Cancer br>MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Costa Rica, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Taiwan, Thailand, United Kingdom, United States
- 2017-05-04
Authorised
- Phase II Trial of MK-3475 in Subjects with mCRPC
- Metastatic Castration-Resistant Prostate Cancer (mCRPC) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, Estonia, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2016-04-15
Authorised
- Phase II Trial of MK-3475 in Subjects with mCRPC with Prior Chemotherapy
- Metastatic Castration-Resistant Prostate Cancer (mCRPC) MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Brazil, Canada, Estonia, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States
- 2016-04-15
Not recruiting
- A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
- Metastatic Castration-resistant Prostate Cancer;Metastatic Breast Cancer
- Australia, Austria, Belgium, Germany, Spain, Sweden, United Kingdom, United States
- 2012-01-23
